- Home
- LSTA vs CGTX Comparison
LSTA vs CGTX Comparison
Compare LSTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- CGTX
- Stock Information
- Founded
- LSTA 1980
- CGTX 2007
- Country
- LSTA United States
- CGTX United States
- Employees
- LSTA 26
- CGTX N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- CGTX Health Care
- Exchange
- LSTA Nasdaq
- CGTX Nasdaq
- Market Cap
- LSTA 24.1M
- CGTX 20.5M
- IPO Year
- LSTA N/A
- CGTX 2021
- Fundamental
- Price
- LSTA $2.61
- CGTX $0.53
- Analyst Decision
- LSTA Strong Buy
- CGTX Strong Buy
- Analyst Count
- LSTA 1
- CGTX 5
- Target Price
- LSTA $15.00
- CGTX $5.63
- AVG Volume (30 Days)
- LSTA 15.8K
- CGTX 1.9M
- Earning Date
- LSTA 08-11-2025
- CGTX 08-07-2025
- Dividend Yield
- LSTA N/A
- CGTX N/A
- EPS Growth
- LSTA N/A
- CGTX N/A
- EPS
- LSTA N/A
- CGTX N/A
- Revenue
- LSTA $1,000,000.00
- CGTX N/A
- Revenue This Year
- LSTA N/A
- CGTX N/A
- Revenue Next Year
- LSTA N/A
- CGTX N/A
- P/E Ratio
- LSTA N/A
- CGTX N/A
- Revenue Growth
- LSTA N/A
- CGTX N/A
- 52 Week Low
- LSTA $1.87
- CGTX $0.22
- 52 Week High
- LSTA $4.20
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- LSTA 50.61
- CGTX 67.18
- Support Level
- LSTA $2.36
- CGTX $0.29
- Resistance Level
- LSTA $3.07
- CGTX $0.34
- Average True Range (ATR)
- LSTA 0.23
- CGTX 0.03
- MACD
- LSTA 0.02
- CGTX 0.01
- Stochastic Oscillator
- LSTA 37.50
- CGTX 92.26
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.